中國三江化工(02198.HK):2022年淨虧3.08億元
格隆匯3月28日丨中國三江化工(02198.HK)發佈公吿,截至2022年12月31日止年度,收益為人民幣88.18億元,同比下降7.2%;公司股東應占純虧3.08億元,上年同期公司股東應占純利3.81億元;基本每股虧損26.18分。
回顧年度內,集團收益減少約7.2%,主要是由於2022年集團主要產品(即環氧乙烷、乙二醇及聚丙烯)的平均售價較2021年下跌約3.3%至約13.5%。2022年度,集團的整體毛利率大幅下降約7.6%至約毛虧率約0.7%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.